These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1012 related articles for article (PubMed ID: 27836992)

  • 1. Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.
    Krawczyk M; Rau M; Schattenberg JM; Bantel H; Pathil A; Demir M; Kluwe J; Boettler T; Lammert F; Geier A;
    J Lipid Res; 2017 Jan; 58(1):247-255. PubMed ID: 27836992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
    Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
    Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic determinants of hepatic steatosis and serum cytokeratin-18 fragment levels in Taiwanese children.
    Lin YC; Chang PF; Chang MH; Ni YH
    Liver Int; 2018 Jul; 38(7):1300-1307. PubMed ID: 29314568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Membrane-bound O-Acyltransferase7 rs641738 Variant in Pediatric Nonalcoholic Fatty Liver Disease.
    Di Sessa A; Umano GR; Cirillo G; Del Prete A; Iacomino R; Marzuillo P; Del Giudice EM
    J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):69-74. PubMed ID: 29601441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the association of a variant in PNPLA3 and TM6SF2 with fibrosis progression in patients with chronic hepatitis C infection after eradication: A retrospective study.
    Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
    Gene; 2022 Apr; 820():146235. PubMed ID: 35143946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.
    Longo M; Meroni M; Paolini E; Erconi V; Carli F; Fortunato F; Ronchi D; Piciotti R; Sabatini S; Macchi C; Alisi A; Miele L; Soardo G; Comi GP; Valenti L; Ruscica M; Fracanzani AL; Gastaldelli A; Dongiovanni P
    Cell Mol Gastroenterol Hepatol; 2022; 13(3):759-788. PubMed ID: 34823063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
    Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of
    Elmansoury N; Megahed AA; Kamal A; El-Nikhely N; Labane M; Abdelmageed M; Daly AK; Wahid A
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.
    Stickel F; Buch S; Nischalke HD; Weiss KH; Gotthardt D; Fischer J; Rosendahl J; Marot A; Elamly M; Casper M; Lammert F; McQuillin A; Zopf S; Spengler U; Marhenke S; Kirstein MM; Vogel A; Eyer F; von Felden J; Wege H; Buch T; Schafmayer C; Braun F; Deltenre P; Berg T; Morgan MY; Hampe J
    Am J Gastroenterol; 2018 Oct; 113(10):1475-1483. PubMed ID: 29535416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C.
    Petta S; Maida M; Grimaudo S; Pipitone RM; Macaluso FS; Cabibi D; Cammà C; Di Marco V; Sferrazza S; Craxì A
    Liver Int; 2016 Feb; 36(2):198-204. PubMed ID: 26259026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
    Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
    Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers.
    Krawczyk M; Bantel H; Rau M; Schattenberg JM; Grünhage F; Pathil A; Demir M; Kluwe J; Boettler T; Weber SN; Geier A; Lammert F;
    J Hum Genet; 2018 May; 63(5):621-626. PubMed ID: 29483677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
    Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
    Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
    Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
    Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Basyte-Bacevice V; Skieceviciene J; Valantiene I; Sumskiene J; Petrenkiene V; Kondrackiene J; Petrauskas D; Lammert F; Kupcinskas J
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non-alcoholic fatty liver disease in children.
    Lee KJ; Moon JS; Kim NY; Ko JS
    Pediatr Obes; 2022 Feb; 17(2):e12852. PubMed ID: 34490745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study).
    Käräjämäki AJ; Hukkanen J; Kauma H; Kesäniemi YA; Ukkola O
    Scand J Clin Lab Invest; 2020; 80(2):106-113. PubMed ID: 31851849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
    Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
    Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
    Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
    Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy.
    Di Costanzo A; Belardinilli F; Bailetti D; Sponziello M; D'Erasmo L; Polimeni L; Baratta F; Pastori D; Ceci F; Montali A; Girelli G; De Masi B; Angeloni A; Giannini G; Del Ben M; Angelico F; Arca M
    Sci Rep; 2018 Feb; 8(1):3702. PubMed ID: 29487372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.